Search - tctmd.com

Displaying 241 - 260 of 671

Sort: Relevancy | Date

Presentation

Impact of Proton Pump Inhibitors (PPIs) on GI Bleeding Associated With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Post-MI Patients Taking Antithrombotics

Presenter: Schjerning Olsen

October 28, 2015

Presentation

ADAPT-DES Subanalaysis: Proton Pump Inhibitors (PPIs), Platelet Reactivity, and Cardiovascular Outcomes After DES in Clopidogrel-Treated Patients

Presenter: Giora Weisz

October 28, 2015

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

Presentation

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Presenter: Dean J. Kereiakes

October 22, 2015

Presentation

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

Presenter: Bruce R. Brodie

October 08, 2015

Presentation

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

Presenter: JA. Gutierrez

October 05, 2015

Presentation

The Comparative Efficacy of Bivalirudin Is Markedly Attenuated by Use of Radial Access

Presenter: E. Perdoncin

October 02, 2015

Presentation Aortovascular 2015

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Presenter: Michael R. Jaff

September 18, 2015

Presentation

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Presenter: Tobias Geisler

September 18, 2015

Presentation

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Presenter: R. Valenti

September 17, 2015

Presentation

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Presenter: Gregg W. Stone

September 15, 2015

Presentation ESC 2015

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Presenter: Marco Valgimigli

September 01, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Presenter: F. Costa

August 21, 2015

Presentation

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

Presenter: Connie N. Hess

August 03, 2015

Presentation

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

Presenter: K. Tsujita

July 28, 2015

Presentation SCCT 2015

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

Presenter: Maros Ferencik

July 18, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

Presentation

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Presenter: Charles V. Pollack Jr

June 24, 2015

Advertisement

Impact of Proton Pump Inhibitors (PPIs) on GI Bleeding Associated With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Post-MI Patients Taking Antithrombotics

ADAPT-DES Subanalaysis: Proton Pump Inhibitors (PPIs), Platelet Reactivity, and Cardiovascular Outcomes After DES in Clopidogrel-Treated Patients

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events

The Comparative Efficacy of Bivalirudin Is Markedly Attenuated by Use of Radial Access

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Use and Outcomes of Triple Therapy Among Older Patients With Acute MI and A-fib

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content